These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7427980)

  • 1. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
    Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of I.V. glucagon administration on selected metabolic parameters in patients with type IIa, IIb and IV primary hyperlipoproteinaemia.
    Andĕl M; Brodan V; Kucerová L; Brodanová M
    Acta Univ Carol Med (Praha); 1980; 26(5-6):271-92. PubMed ID: 7347126
    [No Abstract]   [Full Text] [Related]  

  • 3. Early and late results of coronary artery bypass in patients with hyperlipoproteinemia.
    Hanson EC; Levine FH; Adzick NS; Lees RS; Daggett WM; Austen WG; Buckley MJ
    J Thorac Cardiovasc Surg; 1980 Mar; 79(3):372-80. PubMed ID: 6965512
    [No Abstract]   [Full Text] [Related]  

  • 4. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 5. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
    Uccella R; Morenghi R; Agosti C; Saponati G
    Artery; 1983; 11(5):400-12. PubMed ID: 6661043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum cholesterol and triglyceride levels in patients with type II hyperlipoproteinemia treated with probucol].
    Markiewicz M; Rymar B; Horubała-Bielak G; Koziara Z
    Wiad Lek; 1984 Oct; 37(19):1489-93. PubMed ID: 6528586
    [No Abstract]   [Full Text] [Related]  

  • 8. The influence of a no-sugar diet on the composition of VLDL-fraction in patients with idiopathic hyperlipoprotenemia of type IIb and IV.
    Cybulska B; Naruszewicz M; Kłosiewicz-Latoszek L; Szostak WB; Chotkowska E
    Mater Med Pol; 1980; 12(4):286-92. PubMed ID: 7266054
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fatty acid metabolism in primary hyperlipoproteinemia (HLP) (author's transl)].
    Reuter W
    Dtsch Z Verdau Stoffwechselkr; 1979; 39(3):124-9. PubMed ID: 520271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 13. [The combination of psoriasis with different types of lipoproteinemias. 2. The characteristics of the dyslipoproteinemias caused by disorders in triacylglyceride transport in psoriasis].
    Keshileva ZB; Kosukhin AB; Polevaia LG
    Vestn Dermatol Venerol; 1990; (5):7-11. PubMed ID: 2402946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subfractions of HDL cholesterol. Occurrence in hyperlipoproteinemia type IIa and IV].
    Mertz DP; Thuilot G; Bürvenich K
    Fortschr Med; 1986 Jul; 104(26):508-10. PubMed ID: 3744260
    [No Abstract]   [Full Text] [Related]  

  • 15. [Preliminary evaluation of the usefulness of determination of apolipoprotein B. cholesterol and VLDL triglyceride concentrations in the early diagnosis of type IV hyperlipoproteinemia].
    Bobilewicz D; Kotlicka J; Grajnert K
    Pol Tyg Lek; 1981 Mar; 36(9):325-6. PubMed ID: 7267451
    [No Abstract]   [Full Text] [Related]  

  • 16. [Familial hypercholesterolemia. Study of a family].
    Ahumada-Ayala M; Núñez-Pulache A; Lozano-Castañeda O; Rull JA; Valles VE; Wong B
    Rev Invest Clin; 1984; 36(3):269-75. PubMed ID: 6515160
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo platelet activity and lipoprotein patterns in coronary artery disease.
    Goubran F; Maklady F; Saad M; el-Ashry M
    Wien Klin Wochenschr; 1986 Apr; 98(7):209-11. PubMed ID: 3705598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term effects of a glycosaminoglycan on plasma lipids].
    Avogaro P; Bittolo-Bon G; Alessandrini P
    Clin Ter; 1981 Jul; 98(1):47-61. PubMed ID: 7249572
    [No Abstract]   [Full Text] [Related]  

  • 20. [Rapid changes in blood lipid parameters induced by glucuronyl glucosamine glycan sulfate in obese diabetic and hyperlipidemia patients].
    Ferlito S; La Spina E; Fichera C; Cultrera E; Patanè M; Ciulla P
    Arch Sci Med (Torino); 1982; 139(4):441-8. PubMed ID: 7168636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.